BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases
March 30 Omeros Corp
* Omeros reports more positive data in OMS721 phase 2 trial in renal diseases
* Phase 3 program slated for this year
* Consistent with all other OMS721 clinical trials, no significant safety concerns have been observed
* Preparing breakthrough application and phase 3 protocol for discussion with FDA; phase 3 trial in IGAN expected to begin this year
* New data corroborate and expand on trial results reported in Q4 of 2016 Source text for Eikon: Further company coverage: